| Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis C Villanueva, F Torres, SK Sarin, HA Shah, D Tripathi, A Brujats, ... Journal of hepatology 77 (4), 1014-1025, 2022 | 81 | 2022 |
| Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan, A Brujats, ... Journal of hepatology 75 (3), 589-599, 2021 | 53 | 2021 |
| Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis E Alvarado-Tapias, A Ardevol, M Garcia-Guix, R Montañés, O Pavel, ... Journal of Hepatology 73 (4), 829-841, 2020 | 43 | 2020 |
| Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis J Reiniš, O Petrenko, B Simbrunner, BS Hofer, F Schepis, M Scoppettuolo, ... Journal of Hepatology 78 (2), 390-400, 2023 | 15 | 2023 |
| Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with β-blockers and ligation A Ardevol, E Alvarado-Tapias, M Garcia-Guix, A Brujats, L Gonzalez, ... Digestive and Liver Disease 52 (9), 1017-1025, 2020 | 15 | 2020 |
| Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a … C Villanueva, F Torres, SK Sarin, HA Shah, D Tripathi, A Brujats, ... J Hepatol 77 (4), 1014-1025, 2022 | 11 | 2022 |
| Stratified efficacy of first-line therapy to prevent first variceal bleeding according to previous decompensation of cirrhosis. A competing-risk meta-analyses of individual … C Villanueva, V Sapena, GH Lo, YS Seo, HA Shah, V Singh, D Tripathi, ... Journal of Hepatology 77, S625-S626, 2022 | 3 | 2022 |
| Carvedilol plus Simvastatin modulates systemic inflammation in cirrhosis with portal hypertension and non-response to B-blockers: randomised double-blind study E Alvarado-Tapias, R Montañés, A Brujats, B Cuyas, MG Guix, C Pujol, ... Journal of Hepatology 77, S91, 2022 | 2 | 2022 |
| Carvedilol improves risk of decompensation and survival in compensated cirrhosis. A competing-risk meta-analysis of individual patient data C Villanueva, F Torres, HA Shah, D Tripathi, SK Sarin, A Brujats, ... Journal of hepatology 75, S378-S380, 2021 | 2 | 2021 |
| Predictors of the need for necrosectomy in patients with walled-off pancreatic necrosis treated with lumen apposition metal stents L González-González, S Bazaga, M Murzi, A Brujats, M Trias, B de Riba, ... Surgical Endoscopy, 1-8, 2021 | 2 | 2021 |
| Hemodynamic response determines further decompensation and survival in patients with decompensated cirrhosis C Pujol, MG Guix, A Brujats, E Alvarado-Tapias, A Huerta, B Cuyas, ... Journal of Hepatology 78, S78-S79, 2023 | 1 | 2023 |
| Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes M Garcia‐Guix, A Ardevol, V Sapena, E Alvarado‐Tápias, A Huertas, ... Liver International, 2024 | | 2024 |
| EXAMINING THE THERAPEUTIC LANDSCAPE OF BETA-BLOCKERS IN PORTAL HYPERTENSION A Brujats, C Villanueva Clinical and Molecular Hepatology, 2024 | | 2024 |
| Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis: a retrospective study B Cuyàs, A Huerta, M Poca, E Alvarado-Tapias, A Brujats, E Román, ... Scientific Reports 14 (1), 2718, 2024 | | 2024 |
| Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing‐risk meta‐analysis of individual participant data C Villanueva, V Sapena, GH Lo, YS Seo, HA Shah, V Singh, D Tripathi, ... Alimentary pharmacology & therapeutics 59 (3), 306-321, 2024 | | 2024 |
| INFLUENCE OF MAFLD ON LONG-TERM OUTMES AFTER VIRAL ERADICATION IN HCV-RELATED CIRRHOSIS WITH PORTAL HYPERTENSION E Alvarado-Tapias, S Lens, G Semmler, A Brujats, M Abadia, E Llop, ... HEPATOLOGY 78, S1393-S1395, 2023 | | 2023 |
| Worsening of low-grade systemic inflammation heralds decompensation in patients with compensated cirrhosis R Sánchez-Aldehuelo, C Villanueva, J Genesca, JCG Pagan, A Brujats, ... Journal of Hepatology 77, S370, 2022 | | 2022 |
| Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis B Cuyas, A Huerta, M Poca, E Alvarado-Tapias, A Brujats, E Roman, ... Journal of Hepatology 77, S900, 2022 | | 2022 |
| Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis O Petrenko, J Reiniš, B Simbrunner, B Hofer, PE Rautou, L Moga, ... Journal of Hepatology 77, S502-S503, 2022 | | 2022 |
| P ortalpressuredecreasi ngeffectof β-blockers in cirrhosis with clinically significant portal hypertension according to the components of metabolic syndrome A BRUJATS, B CUYÀS, E ALVARADO, C PUJOL, A MOMBIELA, C ROIG, ... Age (y) 62 (11), 0, 2022 | | 2022 |
